GAMING

Biosof LLC, a developer and distributor of computational solutions for the Pharmaceutical, Biotechnology, Agro-technology and Homeland Security industries, announces its collaboration with IBM to provide a server platform for PredictProtein, a solution that explores, analyzes and interprets genomics data. The collaboration enables customers to use PredictProtein through a Virtual Private Network (VPN) or on-site installation while running on IBM high-performance computing hardware. The new platform is showcased at the IBM booth at the ISMB 2008 Conference in Toronto, July 19-23, 2008. IBM offers the broadest portfolio of high-performance computing solutions optimized for the needs of proteomics with its System x clusters as well as its Cell Broadband Engine-based architectures. Additionally, IBM Power technology clustered in large, dense SMPs can handle the most challenging problems facing researchers and scientists. Power technology is also available in compact blade form-factors. Traditional proteomics research involves lab experiments that require extended time and investment to produce verified data from a limited range of input. In the race to find answers, PredictProtein was developed to accelerate the research process to cover more ground and predict the most -- and least -- useful targets more accurately for more efficient investments of time and money. As a comprehensive resource for protein sequence analysis, PredictProtein incorporates cutting-edge tools for protein structure and function prediction including algorithms providing prediction for: -- Binding/active sites -- Sub-cellular localization -- Domain boundaries -- Fold recognition -- Inter-residue contacts -- Regions lacking regular structure -- Secondary structure -- Solvent accessibility -- Transmembrane, globular and coiled coil regions -- Disulfide bonds "Working with IBM provides our customers the unique opportunity to combine a secure infrastructure and cutting-edge hardware needed to run our highly resource-intensive algorithms," says Dr. Burkhard Rost of Biosof.